Novartis announces cut to multiple drug research programmes in 2022 full-year report
Pharmafile
FEBRUARY 2, 2023
Novartis, a Swiss pharmaceutical company, has announced in its 2022 full-year report that it is cutting several of their programmes, including their Huntington’s disease trial.
Let's personalize your content